Загрузка...
Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis
PURPOSE: A population pharmacokinetic model was developed for nintedanib in patients with non-small cell lung cancer (NSCLC) or idiopathic pulmonary fibrosis (IPF). The effects of intrinsic and extrinsic patient factors on exposure of nintedanib and its main metabolite BIBF 1202 were studied. METHOD...
Сохранить в:
| Опубликовано в: : | Cancer Chemother Pharmacol |
|---|---|
| Главные авторы: | , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Springer Berlin Heidelberg
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5754397/ https://ncbi.nlm.nih.gov/pubmed/29119292 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-017-3452-0 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|